Prognostic impact of CD30 expression in de novo DLBCL. (A-B) Overall survival (OS) (A) and progression-free survival (PFS) (B) of patients with CD30⁺ vs CD30^– DLBCL in the training set. (C) OS of patients with CD30⁺ vs CD30^– DLBCL in the validation set. These patients were part of an independent cohort of 442 patients with available survival information (supplemental Table 1). (D) OS of patients with CD30⁺ vs CD30^– DLBCL in combined training and validation sets. See Figure 2 in the article by Hu et al that begins on page 2715.